SCHEMBL4301974

SCHEMBL4301974

CN1CCN(c2cccc(C(=O)N3CC(c4ccccc4F)C3)n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B14 Q9BPX1 2/20 0.51
USP2 O75604 1/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KMT2A Q03164 1/20 0.45
PRKCQ Q04759 1/20 0.44
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTR3E A5X5Y0 3/20 0.41
HTR3B O95264 3/20 0.41
HTR3A P46098 3/20 0.41
HTR3D Q70Z44 3/20 0.41
HTR3C Q8WXA8 3/20 0.41
CHRM4 P08173 1/20 0.41
GBA1 P04062 1/20 0.41
PROKR1 Q8TCW9 1/20 0.40
IRAK4 Q9NWZ3 1/20 0.39
PDE10A Q9Y233 1/20 0.39
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4301946 0.92 PROKR1 (0.51) HSD17B14USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL3467150 0.90 HSD17B14 (0.50) HSD17B14USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL4304173 0.89 HSD17B14 (0.47) HSD17B14USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL4300878 0.88 PROKR1 (0.46) HSD17B14KMT2APRKCQMAPTHTR3E
SCHEMBL3466779 0.83 HSD17B14 (0.49) HSD17B14USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL3467772 0.82 HSD17B14 (0.48) HSD17B14USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL4295123 0.82 HSD17B14 (0.50) HSD17B14USP2MAPK1SMN1; SMN2PRKCQ
SCHEMBL3469979 0.81 USP2 (0.52) HSD17B14USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL4294496 0.81 HSD17B14 (0.48) HSD17B14USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL4294490 0.81 HSD17B14 (0.48) HSD17B14USP2MAPK1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders HTR6, HTR5A, TPH1 HSD17B14 2214/4885USP2 4670/4885MAPK1 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.